

*Torgomyan A.¹, Saroyan M.², Hovhannisyan S.³, Mashinyan K.⁴,
Yessayan L.⁵, Hakobyan G.⁶*

COVID-19 Pathogenesis in the oral cavity: A Review on Oral Impairments and Manifestations

¹Associate professor, Department of Physiology,
Yerevan State Medical University after M. Heratsi, Armenia

²Senior lecturer, Department of Physiology,
Yerevan State Medical University after M. Heratsi, Armenia

³Associate professor, Department of Prosthodontics,
Yerevan State Medical University after M. Heratsi, Armenia

⁴Associate professor, Department of Prosthodontics,
Yerevan State Medical University after M. Heratsi, Armenia

⁵Professor, Head of Dept. of Therapeutic Dentistry,
Yerevan State Medical University after M. Heratsi, Armenia

⁶Professor, Head of Dept. of Oral and Maxillofacial Surgery
Yerevan State Medical University after M. Heratsi, Armenia

Abstract. With COVID-19, along with other organ systems, symptoms can also appear in the oral cavity.

COVID-19 can cause a number of pathological conditions in the oral cavity of patients, candidiasis, xerostomia, recurrent herpetic lesions, ulcers, vesicles, desquamative gingivitis have been reported, the tongue, palate, lips, gums and buccal mucosa may be affected. Patients with COVID-19 may have difficulty swallowing, burning sensation, most patients have impaired taste and smell.

However it is still impossible to draw a clear parallel between the manifestations of dental diseases and the severity of the coronavirus infection, since too little statistical data and clinical observations are available therefore needed for further investigation.

The goal of this review was to compile a list of COVID-19 symptoms in oral tissues and analyze the potential etiopathogenesis that may influence the development of these oral lesions.

The key terms were used to search international databases for information. A total of 50 sources on relevant topics were chosen. These preliminary data explain the underlying mechanism oral lesions in Covid-19, and will help on future preventive strategies in clinical practice and in everyday life.

Key words: coronavirus, oral cavity, lesions, mucosa.

Introduction

SARS-CoV-2, discovered in 2019, caused the coronavirus illness (COVID-19), and was the cause of the current COVID-19 epidemic that has affected a large part of the world's population [1, 2].

Diagnosis of COVID-19 done using PCR, the material is taken from the pharynx, secretions from

the lower respiratory tract [3]. With COVID-19, the most common symptoms are raising temperature, runny nose, cough, fatigue, complicated shortness of breath, taste and smell disturbance, and pneumonia [4].

The oral cavity is one of the main entry routes for SARS-CoV-2, inflammatory enzymes and che-

micals accumulate in the gingival sulcus and promote microbial colonization, resulting in mucosal changes [5].

With the above, the purpose of this article is to review pathogenesis and oral manifestations COVID-19.

Materials and methods

For the review, 50 sources were selected using the PubMed and Scopus databases. The key terms: SARS-CoV-2 infection, oral manifestations of COVID-19, lesions of the oral mucosa in patients with COVID-19, pathogenesis of COVID-19 in the oral cavity, SARS-CoV-2 in saliva, taste impairment at COVID-19, were used to search for information in international databases.

Due to the presence of ACE2 receptors, the oral mucosa is highly susceptible to SARS-CoV-2 infection. After contact is established to initiate viral entry into the cell, transmembrane serine protease 2 is one of the enzymes required to cleave the binding protein S. The virus, penetrating inside the cell, using the mechanism of the host cell, releases the genetic material and begins to duplicate it [6].

One of the main effects of SARS-CoV-2 infection is formation of an immunological response.

The penetration of macrophages and neutrophils into the affected tissue is accompanied by a strong production of cytokines and a weak interferon response, resulting in a cytokine storm [7, 8].

SARS-CoV-2 is thought to have many entry points into human cells [9]. The receptor–protease-mediated mode of entry, on the other hand, is significant because it boosts viral infectivity [10].

Transmembrane protease serine Serine 2 (TMPRSS2) is a key protease in SARS-CoV-2 infection and is a prospective COVID-19 camostat mesylate [11–19].

The spike protein (SP) is involved in binding to the cell membrane, a process that is triggered by certain enzymes such as furin and these proteases is a critical factor in viral infection [20, 21].

Immunohistochemical and molecular biological studies in the oral cavity showed higher levels of ACE2 expression in the surface and epithelium and stratum corneum of the tongue than in the gingiva [22, 23].

However, ACE2 expression varied between individuals, female hormones [24], salt [25] and smoking [26], among others, alter ACE2 expression. The

infectious potential of the tongue may be limited by the surface cells that secrete it [27]. SARS-CoV infected cells remain in the oral cavity and aspiration of these cells may be associated with LRT23 infection [28].

Saliva, on the other hand, contains a large number of protease inhibitors, according to the database analysis. Infected individuals may experience moderate symptoms such as fever, tiredness, myalgia, and a dry cough [29].

In the early stages of COVID-19, symptoms such as altered taste perception, dysgeusia, and burning sensation in the mouth have been found [30], as the disease progressed, patients also developed ulcerative lesions or *Candida albicans* are mostly on the tongue, palate, lip, and cheek [31, 32, 33].

One of the symptoms of COVID-19 is altered taste perception, dysgeusia and a burning sensation in the mouth [30], some patients also developed ulcerative lesions, a fungal infection mainly on the tongue, palate, lips and cheeks [31–33].

Dysgeusia (various taste disorders) is one of the symptoms often found in patients with COVID-19. According to this 45 percent overall taste disorder prevalence, 38 percent dysgeusia, 35 percent hypogeusia, and 24 percent ageusia. In the genesis of loss of taste lies neurotropism, an important role is played by the crossing of the olfactory epithelium directly through the lamina cribrosa and reaching the central nervous system [34, 35].

Furthermore, when compared to patients who did not have COVID-19 but had similar symptoms, there was a strong link between taste problems and COVID-19 positivity.

Oral mucosal lesions, unlike taste problems, were recorded in only a few case reports, leading to debate over whether this type of illness is caused directly by SARS-CoV-2 or is a later manifestation. Nonetheless, the manifestations included ulcers, blisters, macules, and plaques that varied in amount, color look, and location.

Ulcers were the most common lesions develop as a result of the immunosuppression inherent in COVID-19 disease. According to Kitakawa's observations, ulcerative lesions were most common in moderate to severe COVID-19, and the occurrence of ulcers was linked to herpes [36].

In the immunosuppression inherent in COVID-19, *C. albicans* is part of the oral microbiome of a healthy

person; may affect mucous membranes. This damage, according to Villarroel-Dorrego et al., is a side effect of COVID-19 and not a direct result of SARS-CoV-23 [37].

Geographic tongue has also been observed in patients with COVID-19, despite the fact that these conditions are very common in the general population [37].

According to Jimenez-Cauhe histological studies, oral lesions may be the result of thrombotic mucosal vessel injury and subsequent vasculitis [38].

COVID-19 patients have also been reported to exhibit enanthem-like lesions Petechiae, erythematous macules, and erythematous-vesicular patterns in the oral mucosa are among these, which are frequently linked with subsequent viral clinical symptoms. In the buccal mucosa of patients, viral infection manifested itself in a variety of ways [39, 40].

It is unusual to see a divergent pattern of mucosal lesions caused by a single pathogen [41]. Cox et al. emphasized the importance of co-infection research in severe respiratory diseases [42].

Antibiotics are often given to admitted patients, but little information on bacterial sensitivity is provided [42]. In addition, the majority of patients

experienced oral mucosal injury throughout their hospitalization, implying that coinfections, immune compromise, or adverse drug reactions to COVID-19 treatment were to blame.

Many fatal COVID-19 cases were found to have bacterial and fungal coinfections, according to studies [43].

These data suggested that the mouth cavity should be considered a high-risk area for Covid-19 infection [44–50]. However, it is still impossible to draw a clear parallel between the manifestations of dental diseases and the severity of the coronavirus infection, since too little statistical data and clinical observations are available.

These preliminary data explain the underlying mechanism oral lesions in Covid-19, and will help on future preventive strategies in clinical practice and in everyday life.

Declaration of Competing Interest

No competing financial interests.

Funding

The work was not funded.

REFERENCES

1. Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: progress in diagnostics, therapy and vaccination. *Theranostics* 2020; 10 (17): 7821–35. doi: 10.7150/thno.47987
2. Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: the status and perspectives in delivery points of view. *Adv Drug Deliv Rev* 2021;170:1–25. doi: 10.1016/j.addr.2020.12.011
3. Pereira LJ, Pereira CV, Murata RM, Pardi V, Pereira-Dourado SM. Biological and social aspects of Coronavirus Disease 2019 (COVID-19) related to oral health. *Braz Oral Res.* 2020; 34:e041.
4. Wang Y, Li X, Ren L, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) 10.1016/S0140-6736(20)30183-5
5. Xiang Z, Koo H, Chen Q, Zhou X, Liu Y, Simon-Soro A. Potential implications of SARS-CoV-2 oral infection in the host microbiota. *J Oral Microbiol* 2020; 13 (1): 1853451. doi: 10.1080/20002297.2020.1853451
6. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol* 2021;19(3):141–54. doi: 10.1038/s41579-020-00459-7
7. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. *J Med Virol.* 2021;93(1):250–6. doi: 10.1002/jmv.26232.
8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020;324(8):782–93. doi: 10.1001/jama.2020.12839
9. Mahyuddin AP, Kanneganti A, Wong J, Dimri PS, Su LL, Biswas A, Illanes SE, Mattar C, Huang RJ, Choolani M. Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV -2. *Prenat. Diagn* 2020; 40(13):1655-1670. doi: 10.1002/pd.5765
10. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. *Proc. Natl. Acad. Sci. USA* 2005; 102(35):12543–12547. doi: 10.1073/pnas.0503203102
11. Song H, Seddighzadeh B, Cooperberg MR, Huang FW. Expression of ACE2, the SARS-CoV-2 Receptor and TMPRSS2 in Prostate Epithelial Cells. *Eur. Urol.* 2020; 78(2):296–298. doi: 10.1016/j.eururo.2020.04.065

12. Kawase M, Shirato K, Van Der Hoek L, Taguchi F, Matsuyama S. Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry. *J. Virol.* 2012; 86(12):6537–6545. doi: 10.1128/JVI.00094-12.
13. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J. Pathol.* 2020; 251 (3): 228–248. doi: 10.1002/path.5471
14. Darbani B. The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues. *Int. J. Environ. Res. Public Heal.* 2020; 17(10):3433. doi: 10.3390/ijerph17103433
15. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020; 395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8
16. Wang WK, Chen SY, I-Jung Liu IJ, Chen YC, Chen HL, Chao-Fu Yang CF, Chen PJ, Yeh SH, Kao CH, Huang LM et al. Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. *Emerg. Infect. Dis.* 2004; 10 (7): 1213–1219. doi: 10.3201/eid1007.031113
17. Bouctcher E, Matrosovich T, Beyerle M, Klenk H.-D, Garten W, Matrosovich M. Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway Epithelium. *J. Virol.* 2006;80(19):9896–9898. doi: 10.1128/JVI.01118-06
18. Tanabe LM, List K. The role of type II transmembrane serine protease-mediated signaling in cancer. *FEBS J.* 2017; 284 (10): 1421–1436. doi: 10.1111/febs.13971
19. Collin J, Queen R, Zerti D, Dorgau B, Georgiou M, Djidrovski I, Hussain R, Coxhead JM, Joseph A, Rooney P et al. Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface. *Ocul. Surf.* 2021; 19: 190–200. doi: 10.1016/j.jtos.2020.05.013
20. Carreras-Presas CM, Sónchez JA, Lypez-Sónchez AF, Jané-Salas E, Pérez MLS. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. *Oral Dis.* 2021; 3: 710–712. doi: 10.1111/odi.13382
21. Hasan A, Paray BA, Hussain A, Qadir FA, Attar F Aziz FM, Sharifi M, Derakhshankhah H, Rasti B, Mehrabi M et al. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. *J. Biomol. Struct. Dyn.* 2021; 39 (8): 3025–3033. doi: 10.1080/07391102.2020.1754293
22. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res.* 2020; 176:104742. doi: 10.1016/j.antiviral.2020.104742
23. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. *J. Clin. Periodontol.* 2006; 33(6):401–407. doi: 10.1111/j.1600-051X.2006.00924.x
24. Hamming I, Timens W, Bulthuis M, Lely AT, Navis G, Van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* 2004; 203(2):631–637. doi: 10.1002/path.1570
25. Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. *Pharmacol. Res.* 2020; 157:104833. doi: 10.1016/j.phrs.2020.104833.
26. Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD, Battlle D. Regulation of urinary ACE2 in diabetic mice. *Am. J. Physiol. Physiol.* 2013; 305(4): F600–F611. doi: 10.1152/ajprenal.00600.2012
27. Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin system. *Am. J. Physiol. Integr. Comp. Physiol.* 2018; 315(5):R895–R906. doi: 10.1152/ajpregu.00099.2018
28. Tu Y-P, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, Verma P, Vojta D, Berke EM. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. *New Engl. J. Med.* 2020;383(5):494–496. doi: 10.1056/NEJMc2016321
29. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Lisy K, Qureshi R, Mattis P, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. Aromataris E, Munn Z (Editors) *JBI Man Evid Synth JBI*, 2017. Available from <https://reviewersmanual.joannabriggs.org/>
30. Cuevas-Gonzalez MV, Espinosa-Cristybal LF, Donohue-Cornejo A, Karla Lizette Tovar-Carrillo KL, Saucedo-Acuca RA, Garca-Calderyn AG, Guzmán-Gastelum DA, Cuevas-Gonzalez JC. COVID-19 and its manifestations in the oral cavity: A systematic review. *Medicine* 2021;100(51):e28327. doi: 10.1097/MD.00000000000028327
31. Brandão TB, Gueiros LA, Melo TS et al. Oral lesions in patients with SARS-CoV-2 infection: could the oral cavity be a target organ? *Oral Surg Oral Med Oral Pathol Oral Radiol* 2021;131(2):e45–51. doi: 10.1016/j.oooo.2020.07.014
32. Carreras-Presas MC, Amaro Sánchez J, López-Sánchez AF, Jané-Salas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. *Oral Dis* 2021; 27 Suppl 3: 710–2. doi: 10.1111/odi.13382
33. Rodríguez DM, Jimenez Romera A, Villarroel M. Oral manifestations associated with COVID-19. *Oral Dis* 2020;10.1111/odi.13555. doi: 10.1111/odi.13555. Online ahead of print.

34. Mahmoud MM, Abuhashish HM, Khairy DA, Bugshan AS, Khan AM, Moothedath MM. Pathogenesis of dysgeusia in COVID-19 patients: a scoping review. *Eur Rev Med PharmacolSci* 2021; 25 (2): 1114–34. doi: 10.26355/eurrev_202101_24683
35. Sakaguchi W, Kubota N, Shimizu T et al. Existence of SARS-CoV-2 entry molecules in the oral cavity. *Int J MolSci* 2020; 21 (17): 6000. doi: 10.3390/ijms21176000
36. Kitakawa D, Oliveira FE, Neves De Castro P, Carvalho LFCS. Shortreport - Herpes simplex lesion in the lip semimucosa in a COVID-19 patient. *Eur Rev Med PharmacolSci* 2020; 24 (17): 9151–3. doi: 10.26355/eurrev_202009_22863.
37. Villarroel-Dorrego M, Chacón L, Rosas R, Barrios V, Pernía Y, Velez H. Oral Findings in Patients With COVID-19. *2021; S1578-2190(21):00333-4*. doi: 10.1016/j.adengl.2021.11.028. Online ahead of print.
38. Jimenez-Cauhe J, Ortega-Quijano D, de Perosanz-Lobo D, Burgos-Blasco P, Vacó-Galván S, Fernandez-Guarino M, Fernandez-Nieto D. Enanthem in Patients With COVID-19 and Skin Rash. *JAMA Dermatol.* 2020; 156 (10): 1134–1136. doi:10.1001/jamadermatol.2020.2550
39. Kahraman CF, Çaşkurlu H. Mucosal involvement in a COVID-19-positive patient: A case report. *DermatolTher.* 2020;33(4):e13797. doi: 10.1111/dth.13797
40. Hocková B, Riad A, Valky J, Šulajová Z, Stebel A, Slávik R, Bečková Z, Pokorná A, Klugarová J, Klugar M. Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases. *J Clin Med.* 2021; 10 (4): 581. doi: 10.3390/jcm10040581
41. Galvan Casas C, Catala A, Carretero Hernandez G, Rodriguez-Jimenez P, Fernandez-Nieto D, Rodriguez-Villa Lario A, Navarro Fernandez I, Ruiz-Villaverde R, Falkenhain-Lopez D, Llamas Velasco M, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol.* 2020; 183 (1): 71–77. doi: 10.1111/bjd.19163
42. Cox MJ, Loman N, Bogaert D, O’Grady J. Co-infections: potentially lethal and unexplored in COVID-19. *Lancet Microbe.* 2020; 1 (1): e11. doi: 10.1016/S2666-5247(20)30009-4
43. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020; 395 (10223) :507–513. doi: 10.1016/S0140-6736(20)30211-7
44. Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, De Paula RM, Cembranel AC, Santos-Silva AR, Guerra ENS. Oral mucosal lesions in a COVID-19 patient: New signs or secondary manifestations? *Int J Infect Dis.* 2020; 97: 326–328. doi: 10.1016/j.ijid.2020.06.012
45. Farid H, Khan M, Jamal S, Ghafoor R. Oral manifestations of Covid-19-A literature review. *Rev Med Virol.* 2022; 32 (1): e2248. doi: 10.1002/rmv.2248. Epub 2021 May 24.
46. Kusiak A, Cichońska D, Tubaja M, et al. COVID-19 manifestation in the oral cavity - a narrative literature review. *Acta Otorhinolaryngol Ital.* 2021; 41 (5): 395–400. doi:10.14639/0392-100X-N1584
47. Biadsee A, Biadsee A, Kassem F, et al. . Olfactory and oral manifestations of covid-19: sex-related symptoms - a potential pathway to early diagnosis. *Otolaryngol Head Neck Surg.* 2020; 163: 722–728. <https://doi.org/10.1177/0194599820934380> 10.1177/0194599820934380
48. Marouf N, Cai W, Said KN, et al. Association between periodontitis and severity of COVID-19 infection: a case-control study. *J Clin Periodontol.* 2021; 48: 483–491. <https://doi.org/10.1111/jcpe.13435> 10.1111/jcpe.13435
49. Maheswaran T, Abikshyeet P, Sitra G, Gokulanathan S, Vaithyanadane V, Jeelani S. Gustatory dysfunction. *J Pharm Bioallied Sci.* 6 Suppl. 2014; 6 (Suppl 1): S30-3. doi: 10.4103/0975-7406.137257
50. Vieira LA, Salzano G, Fois AG, Piombino P, De Riu G. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. *Int Forum Allergy Rhinol.* 2020; 10 (9): 1103–1104. doi: 10.1002/alr.22593

Патогенез COVID-19 у порожнині рота: огляд порушень та проявів порожнини рота

Торгоман А., Сароян М., Ованісян С., Машинян К., Есаян Л., Акопян Р.

Резюме. При COVID-19, разом з іншими системами органів, симптоми можуть з’явитися і в ротовій порожнині.

COVID-19 може викликати низку патологічних станів ротової порожнини пацієнтів: кандидоз, ксеростомія, рецидивуючі герпетичні ураження, виразки, пухирці, десквамативний гінгівіт, можливе ураження язика, піднебіння, губ, ясен та слизової оболонки щік.

У хворих на COVID-19 можуть виникати труднощі з ковтанням, відчуття печіння, у більшості пацієнтів порушується смак і нюх.

Проте, провести чітку паралель між проявами стоматологічних захворювань і ступенем тяжкості коронавірусної інфекції поки що неможливо, оскільки доступно небагато статистичних даних і клінічних спостережень, тому необхідні подальші дослідження.

Метою цього огляду було скласти список симптомів COVID-19 у тканинах ротової порожнини та проаналізувати потенційний етіопатогенез, який може вплинути на розвиток цих уражень ротової порожнини.

Ключові терміни використовувалися для пошуку інформації в міжнародних базах даних, всього було обрано 50 джерел відповідної тематики.

Ці попередні дані пояснюють основний механізм уражень порожнини рота при Covid-19 і допоможуть розробити майбутні профілактичні стратегії в клінічній практиці та в повсякденному житті.

Ключові слова: коронавірус, ротова порожнина, ураження, слизова оболонка

Патогенез COVID-19 в полости рта: обзор нарушений и проявлений полости рта

Торгоман А., Сароян М., Ованнисян С., Машинян К., Есяян Л., Акопян Г.

Резюме. При COVID-19 наряду с другими системами органов симптомы могут проявляться и в ротовой полости.

COVID-19 может вызывать ряд патологических состояний в полости рта пациентов, сообщалось о кандидозе, ксеростомии, рецидивирующих герпетических поражениях, язвах, везикулах, десквамативном гингивите, возможно поражение языка, неба, губ, десен и слизистой оболочки щек. У пациентов с COVID-19 могут возникать затруднения при глотании, чувство жжения, у большинства пациентов нарушены вкус и обоняние.

Однако провести четкую параллель между проявлениями стоматологических заболеваний и тяжестью течения коронавирусной инфекции пока невозможно, так как имеется слишком мало статистических данных и клинических наблюдений, поэтому необходимы дальнейшие исследования.

Цель этого обзора состояла в том, чтобы составить список симптомов COVID-19 в тканях полости рта и проанализировать потенциальный этиопатогенез, который может влиять на развитие этих поражений полости рта.

Ключевые термины использовались для поиска информации в международных базах данных, всего было отобрано 50 источников по актуальным темам.

Все предварительные данные объясняют основной механизм поражения ротовой полости при Covid-19 и помогут в будущих профилактических стратегиях, клинической практике и повседневной жизни.

Ключевые слова: коронавирус, полость рта, поражения, слизистая оболочка.

Torgomyan A. – MD., PhD associate professor, Department of Physiology,

Yerevan State Medical University after M. Heratsi, Armenia

Saroyan M. MD., PhD – senior lecturer, Department of Physiology,

Yerevan State Medical University after M. Heratsi, Armenia

Hovhannisyan S. – PhD, Associate professor, Department of Prosthodontics,

Yerevan State Medical University after M. Heratsi, Armenia

Mashinyan K. – PhD, Associate professor, Department of Prosthodontics,

Yerevan State Medical University after M. Heratsi, Armenia

Yessayan L. – DMSc, PhD. Professor, Head of Dept. of Therapeutic Dentistry,

Yerevan State Medical University after M. Heratsi, Armenia

Hakobyan G. – DMSc, PhD, Professor, Head of Dept. of Oral and Maxillofacial Surgery

Yerevan State Medical University after M. Heratsi, Armenia

Corresponding Author: professor **Gagik Hakobyan Mailing.**

Address: 0028 Kievyan str. 10 ap. 65. Yerevan, Armenia **Phone:** (+37410)271146, **e-mail:** prom_hg@yahoo.com